In high-risk cardiovascular disease patients, the administration of PCSK9 inhibitors demonstrated a noteworthy decrease in the risk of cerebrovascular diseases, encompassing ischemic stroke and recurrent ischemic stroke (Giugliano et al., 2017b; Goodman et al., 2023). This evidence concerns the gene PCSK9 and cerebrovascular disorder.